AstraZeneca says Symbicort as antiinflammatory reliever reduces attacks in mild asthma

AstraZeneca says Symbicort as anti-inflammatory reliever reduces attacks in mild asthma

These results are published in the New England Journal of Medicine and are being presented at the American Thoracic Society 2019 International Conference. The trial compared Symbicort Turbuhaler with

More From BioPortfolio on "AstraZeneca says Symbicort as anti-inflammatory reliever reduces attacks in mild asthma"